Cohance Lifesciences Q2 FY27: revenue down 14.2% to ₹477 Cr, net profit down 96.5% to ₹2 Cr
Results · Finvezto · 6 Nov 2026 · Cohance Lifesciences (COHANCE)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 477 | +12.9% | -14.2% |
| Operating profit | 35 | +2850.0% | -70.7% |
| Net profit | 2 | +105.1% | -96.5% |
| Operating margin | 7.4% | +7.1 pp | -14.3 pp |
| Net margin | 0.5% | +0.2 pp | -11.3 pp |
Key points
- Cohance Lifesciences reported Q2 FY27 revenue from operations of Rs 476.70 crore, declining 14.2% year-on-year, and an Adjusted EBITDA of Rs 45.80 crore. NSE filing
- Gross margin contracted to 70.8% due to an unfavourable product mix, though management expects H2 FY27 to deliver year-on-year growth in both revenue and EBITDA. NSE filing
- Revenue was ₹477 Cr, down 14.2% on a year earlier and up 12.9% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 17.5%, 15.9%, 0.3%, 7.4%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 29, 8, -45, 2.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.